Stock comparison
Genmab A/S
The Pennant Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
PNTG
The Pennant Group
Market cap
$1.18B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | PNTG | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 61D | GMAB |
| Benjamin Graham | 64C | 78B | PNTG |
| Philip Fisher | 48D | 61C | PNTG |
| Peter Lynch | 25F | 52C | PNTG |
| Joel Greenblatt | 76B | 45D | GMAB |
| Charlie Munger | 68C | 40D | GMAB |
| Terry Smith | 71C | 37D | GMAB |
Side-by-side metrics
| Metric | GMAB | PNTG |
|---|---|---|
| Market cap | $16.5B | $1.18B |
| P/E (TTM) | 6.2x | 39.1x |
| EV/EBIT | 12.0x | 31.7x |
| ROIC (TTM) | 43.78% | 4.96% |
| Gross margin | 93.88% | 14.78% |
| Net margin | 18.23% | 2.96% |
| Revenue CAGR 5y | -18.45% | 21.17% |
| EPS CAGR 5y | -23.48% | 83.65% |
| Debt / Equity | 0.1x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.3x+94%
- Market cap$16.5Bvs $1.18B+93%
- ROIC (TTM)43.78%vs 4.96%+89%
- P/E (TTM)6.2xvs 39.1x+84%
PNTG leads on
- Revenue CAGR 5y21.17%vs -18.45%+187%
- EPS CAGR 5y83.65%vs -23.48%+128%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.